Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.49 |
| ▸ | CDC25B | P30305 | 5/20 | 0.49 |
| ▸ | ACP1 | P24666 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782935 | 0.98 | PTPN1 (0.51) | PTPN1CDC25BACP1LMNAKDM4E | |
| SCHEMBL7239635 | 0.98 | PTPN1 (0.51) | PTPN1CDC25BACP1LMNAKDM4E | |
| SCHEMBL3789174 | 0.98 | PTPN1 (0.51) | PTPN1CDC25BACP1LMNAKDM4E | |
| SCHEMBL28927137 | 0.95 | LMNA (0.54) | PTPN1CDC25BACP1LMNAKDM4E | |
| SCHEMBL20826897 | 0.91 | KDM4E (0.50) | PTPN1CDC25BACP1LMNAKDM4E | |
| SCHEMBL7995598 | 0.87 | HSD17B10 (0.52) | PTPN1CDC25BACP1LMNAKDM4E | |
| SCHEMBL23281434 | 0.83 | ALDH1A1 (0.44) | PTPN1CDC25BACP1LMNAKDM4E | |
| SCHEMBL31440186 | 0.83 | KDM4E (0.42) | PTPN1CDC25BACP1LMNAKDM4E | |
| SCHEMBL7238832 | 0.82 | ALDH1A1 (0.42) | PTPN1CDC25BACP1LMNAKDM4E | |
| SCHEMBL31603 | 0.81 | BACE1 (0.44) | PTPN1CDC25BACP1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608086-B2 | Selective adrenergic receptor alpha 1C antagonists without significant calcium channel activity; treating benign prostatic hyperplasia, intraocular pressure and inhibiting cholesterol synthesis | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-6310076-B1 | TREATING BENIGN PROSTATIC HYPERPLASIA, LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, TREATING DISEASES MEDIATED BY ALPHA-1 RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-10-30 | — | — | US | disclosed |
| US-6211198-B1 | BENIGN PROSTATE HYPERPLASIA; INTRAOCULAR PRESSURE; HYPOTENSIVE AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-5767131-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, INHIBITION OF CHOLESTEROL SYNTHESIS, LOWERING OF INTRAOCULAR PRESSURE; ALPHA-ADRENERGIC RECEPTOR DISEASES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1994022829-A2 | DIHYDROPYRIDINES AND NEW USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193599-A1 | Dihydropyridines and new uses thereof | BPHL, BCKDK, DHCR7 | PTPN1 3545/4885CDC25B 3289/4885ACP1 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.